Safety of Celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance
Seguridad del celecoxib en pacientes con reacciones cutáneas por intolerancia a AAS-AINES
Read
10698
Timeswas read the article
1117
Total PDF
9581
Total HTML
Article information
ISSN: 03010546Original language: English
DOI:10.1157/13108222
The statistics are updated each day
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 132 | 12 | 144 |
| 2025 11 | 423 | 27 | 450 |
| 2025 10 | 298 | 12 | 310 |
| 2025 9 | 225 | 18 | 243 |
| 2025 8 | 254 | 23 | 277 |
| 2025 7 | 243 | 8 | 251 |
| 2025 6 | 223 | 6 | 229 |
| 2025 5 | 226 | 4 | 230 |
| 2025 4 | 244 | 21 | 265 |
| 2025 3 | 161 | 9 | 170 |
| 2025 2 | 152 | 13 | 165 |
| 2025 1 | 177 | 16 | 193 |
| 2024 12 | 146 | 7 | 153 |
| 2024 11 | 111 | 10 | 121 |
| 2024 10 | 128 | 6 | 134 |
| 2024 9 | 150 | 7 | 157 |
| 2024 8 | 103 | 10 | 113 |
| 2024 7 | 126 | 8 | 134 |
| 2024 6 | 94 | 10 | 104 |
| 2024 5 | 98 | 6 | 104 |
| 2024 4 | 98 | 3 | 101 |
| 2024 3 | 94 | 7 | 101 |
| 2024 2 | 118 | 12 | 130 |
| 2024 1 | 127 | 10 | 137 |
| 2023 12 | 144 | 19 | 163 |
| 2023 11 | 224 | 18 | 242 |
| 2023 10 | 158 | 13 | 171 |
| 2023 9 | 127 | 17 | 144 |
| 2023 8 | 93 | 7 | 100 |
| 2023 7 | 101 | 10 | 111 |
| 2023 6 | 108 | 17 | 125 |
| 2023 5 | 121 | 6 | 127 |
| 2023 4 | 124 | 15 | 139 |
| 2023 3 | 99 | 8 | 107 |
| 2023 2 | 126 | 10 | 136 |
| 2023 1 | 79 | 20 | 99 |
| 2022 12 | 75 | 2 | 77 |
| 2022 11 | 65 | 12 | 77 |
| 2022 10 | 60 | 8 | 68 |
| 2022 9 | 57 | 12 | 69 |
| 2022 8 | 61 | 19 | 80 |
| 2022 7 | 63 | 11 | 74 |
| 2022 6 | 70 | 13 | 83 |
| 2022 5 | 68 | 14 | 82 |
| 2022 4 | 67 | 23 | 90 |
| 2022 3 | 77 | 10 | 87 |
| 2022 2 | 41 | 8 | 49 |
| 2022 1 | 70 | 23 | 93 |
| 2021 12 | 57 | 8 | 65 |
| 2021 11 | 69 | 12 | 81 |
| 2021 10 | 64 | 7 | 71 |
| 2021 9 | 74 | 16 | 90 |
| 2021 8 | 52 | 5 | 57 |
| 2021 7 | 48 | 13 | 61 |
| 2021 6 | 34 | 15 | 49 |
| 2021 5 | 47 | 13 | 60 |
| 2021 4 | 93 | 12 | 105 |
| 2021 3 | 43 | 6 | 49 |
| 2021 2 | 12 | 14 | 26 |
| 2021 1 | 13 | 24 | 37 |
| 2020 12 | 0 | 1 | 1 |
| 2020 11 | 0 | 2 | 2 |
| 2020 5 | 0 | 1 | 1 |
| 2020 3 | 0 | 1 | 1 |
| 2019 6 | 0 | 2 | 2 |
| 2019 5 | 0 | 8 | 8 |
| 2019 4 | 0 | 7 | 7 |
| 2018 2 | 5 | 0 | 5 |
| 2018 1 | 8 | 3 | 11 |
| 2017 12 | 6 | 0 | 6 |
| 2017 11 | 10 | 2 | 12 |
| 2017 10 | 6 | 2 | 8 |
| 2017 9 | 16 | 2 | 18 |
| 2017 8 | 12 | 4 | 16 |
| 2017 7 | 18 | 12 | 30 |
| 2017 6 | 23 | 20 | 43 |
| 2017 5 | 22 | 10 | 32 |
| 2017 4 | 21 | 7 | 28 |
| 2017 3 | 5 | 14 | 19 |
| 2017 2 | 17 | 6 | 23 |
| 2017 1 | 17 | 2 | 19 |
| 2016 12 | 16 | 4 | 20 |
| 2016 11 | 27 | 4 | 31 |
| 2016 10 | 30 | 0 | 30 |
| 2016 9 | 26 | 6 | 32 |
| 2016 8 | 14 | 7 | 21 |
| 2016 7 | 10 | 1 | 11 |
| 2016 6 | 20 | 11 | 31 |
| 2016 5 | 18 | 4 | 22 |
| 2016 4 | 19 | 2 | 21 |
| 2016 3 | 34 | 10 | 44 |
| 2016 2 | 21 | 11 | 32 |
| 2016 1 | 26 | 18 | 44 |
| 2015 12 | 28 | 5 | 33 |
| 2015 11 | 19 | 6 | 25 |
| 2015 10 | 26 | 3 | 29 |
| 2015 9 | 30 | 7 | 37 |
| 2015 8 | 11 | 5 | 16 |
| 2015 7 | 11 | 5 | 16 |
| 2015 6 | 9 | 4 | 13 |
| 2015 5 | 12 | 4 | 16 |
| 2015 4 | 17 | 12 | 29 |
| 2015 3 | 16 | 10 | 26 |
| 2015 2 | 21 | 2 | 23 |
| 2015 1 | 36 | 1 | 37 |
| 2014 12 | 32 | 5 | 37 |
| 2014 11 | 18 | 3 | 21 |
| 2014 10 | 28 | 5 | 33 |
| 2014 9 | 32 | 3 | 35 |
| 2014 8 | 23 | 0 | 23 |
| 2014 7 | 12 | 1 | 13 |
| 2014 6 | 23 | 0 | 23 |
| 2014 5 | 16 | 1 | 17 |
| 2014 4 | 8 | 1 | 9 |
| 2014 3 | 40 | 14 | 54 |
| 2014 2 | 47 | 11 | 58 |
| 2014 1 | 44 | 6 | 50 |
| 2013 12 | 46 | 4 | 50 |
| 2013 11 | 33 | 9 | 42 |
| 2013 10 | 44 | 12 | 56 |
| 2013 9 | 39 | 10 | 49 |
| 2013 8 | 44 | 6 | 50 |
| 2013 7 | 42 | 16 | 58 |
| 2013 6 | 17 | 7 | 24 |
| 2013 5 | 34 | 10 | 44 |
| 2013 4 | 18 | 7 | 25 |
| 2013 3 | 18 | 7 | 25 |
| 2013 2 | 14 | 3 | 17 |
| 2013 1 | 6 | 1 | 7 |
| 2012 11 | 1 | 1 | 2 |
| 2012 10 | 2 | 1 | 3 |
| 2007 6 | 1182 | 0 | 1182 |
Show all
